ERBB2 and carcinosarcoma: Due to this finding, a trastuzumab antibody-drug conjugate (T-DXd) was studied in uterine carcinosarcomas where there was a 54% objective response rate in Her2/neu high and 70% in Her2/neu low cases with a median overall progression-free survival of 6.7 months.